Aurinia Pharmaceuticals (AUPH) Shares Outstanding (Weighted Average) (2016 - 2026)

Aurinia Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 11 years, with the latest figure at $132.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 4.71% year-over-year to $132.4 million; the trailing twelve-month figure through Mar 2026 stood at $132.4 million (down 4.71% YoY), and the FY2025 full-year result was $134.4 million, down 6.07% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $132.4 million, down from $134.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $144.0 million in Q1 2024, with the low at $132.4 million in Q1 2026.
• Historically, Shares Outstanding (Weighted Average) has averaged $140.6 million across 5 years, with a median of $141.9 million in 2022.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) gained 11.2% — and 2025, when it declined 6.07%.
• Aurinia Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $141.9 million in 2022, then increased by 0.93% to $143.2 million in 2023, then dropped by 0.12% to $143.1 million in 2024, then slipped by 6.07% to $134.4 million in 2025, then retreated by 1.48% to $132.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $132.4 million (Q1 2026), $134.4 million (Q4 2025), and $135.2 million (Q3 2025), per Business Quant data.